8-K/A 1 d8ka.htm AMENDMENT NO. 1 TO FORM 8-K Amendment No. 1 to Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 14, 2008

 

 

NovaBay Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

California   001-33678   68-0454536

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

5980 Horton Street, Suite 550, Emeryville, CA   94608
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (510) 899-8800

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Explanatory Note

NovaBay Pharmaceuticals, Inc. (the “Company”) hereby amends and supplements its Current Report on Form 8-K dated and filed on May 14, 2008 (the “Form 8-K”) as set forth in this Current Report on Form 8-K/A (the “Form 8-K/A”). The Form 8-K was filed to report, among other things, the announcement of the Company’s financial results for the quarter ended March 31, 2008. This Form 8-K/A is being filed solely to correct a typographical error regarding the Company’s unaudited net loss per share and shares used in per share calculations for the three month period ended March 31, 2007 as set forth in Exhibit 99.1 to the Form 8-K. Except as described herein, the information contained in the Form 8-K has not been updated or amended.

Item 2.02. Results of Operations and Financial Condition.

On May 14, 2008, NovaBay Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2008. A copy of the press release is attached as Exhibit No. 99.1 to this report.

The information contained in this report, including the exhibit attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

99.1    Press Release, dated May 14, 2008, of NovaBay Pharmaceuticals, Inc.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 16, 2008     NOVABAY PHARMACEUTICALS, INC.
    By:   /s/ THOMAS J. PAULSON
      Thomas J. Paulson
      Chief Financial Officer and Treasurer


EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Press Release, dated May 14, 2008, of NovaBay Pharmaceuticals, Inc.